Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE

STAT reports on the hunt for a new Alzheimer’s gene!

You are here:
  1. Home
  2. Research News
  3. STAT reports on the hunt…

A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.

Post navigation

PreviousPrevious post:Big data in Alzheimer’s: Are women more vulnerable to Alzheimer’s disease than men?NextNext post:Biohaven and Alzheimer’s Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate AD.
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

Facebook page opens in new windowRss page opens in new windowMail page opens in new window
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
Copyright 2017 Regents of the University of California.
Go to Top